AURO-CEFUROXIME 250 MG
CEFUROXIME (CEFUROXIME AXETIL) : 250 MG · DIN 02344823 · AURO PHARMA INC
Health Canada status: MARKETED
What is AURO-CEFUROXIME?
AURO-CEFUROXIME 250 MG contains CEFUROXIME (CEFUROXIME AXETIL) : 250 MG. It is listed in the Health Canada Drug Product Database under DIN 02344823, held by AURO PHARMA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 11-Jan-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is AURO-CEFUROXIME used for?
AURO-CEFUROXIME (cefuroxime axetil) is indicated for the treatment of patients with mild to moderately severe infections caused by susceptible strains of the designated organisms in the following diseases: Upper Respiratory Tract Infections Pharyngitis and tonsillitis caused by Streptococcus pyogenes. Otitis Media caused by Streptococcus pneumoniae, Streptococcus pyogenes (group A betahemolytic streptococci), Haemophilus influenzae (beta - lactamase negative and beta - lactamase positive strains) or Moraxella catarrhalis. Sinusitis caused by Moraxella catarrhalis, Streptococcus pneumoniae or Haemophilus influenzae (including ampicillin - resistant strains). Lower Respiratory Tract Infections Pneumonia or bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae (including ampicillin - resistant strains), Haemophilus parainfluenzae, Klebsiella pneumoniae or Moraxella catarrhalis. Skin Structure Infections Skin structure infections caused by Staphylococcus aureus (methicillin susceptible), Streptococcus pyogenes or Streptococcus agalactiae.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02344823 |
|---|---|
| Brand name | AURO-CEFUROXIME |
| Generic / active ingredient | CEFUROXIME (CEFUROXIME AXETIL) : 250 MG |
| Manufacturer | AURO PHARMA INC |
| Strength | 250 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J01DC02 CEFUROXIME |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 11-Jan-2021 |
| Original market date | 2010-04-27 00:00:00 |
How is it stored and handled?
Store between 15°C and 30°C.
How is it supplied?
blister of 6 x 10’s count & bottle pack of 60 tablets
What can be used instead?
Other Canadian products sharing ATC code J01DC02 CEFUROXIME. 9 of 44 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-CEFUROXIME | 250 MG | TABLET | APOTEX INC | MARKETED | DIN 02244393 |
| APO-CEFUROXIME | 500 MG | TABLET | APOTEX INC | MARKETED | DIN 02244394 |
| AURO-CEFUROXIME | 500 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02344831 |
| CEFTIN | 125 MG / 5 ML | GRANULES FOR SUSPENSION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02212307 |
| CEFUROXIME FOR INJECTION, USP | 1.5 G | POWDER FOR SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02241639 |
| CEFUROXIME FOR INJECTION, USP | 750 MG | POWDER FOR SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02241638 |
| JAMP CEFUROXIME | 250 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02547198 |
| JAMP CEFUROXIME | 500 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02547201 |
| CEFTIN - PWR 250MG/SACHET | 250 MG | POWDER | GLAXOSMITHKLINE INC | CANCELLED POST MARKET | DIN 02212293 |
| CEFTIN - TAB 250MG | 250 MG | TABLET | GLAXOSMITHKLINE INC | CANCELLED POST MARKET | DIN 02212277 |
Who else supplies CEFUROXIME worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CEFUROXIME appears in 39 registered pack listings across 4 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.